share_log

Medicure Inc. (OTCMKTS:MCUJF) Sees Significant Increase in Short Interest

Medicure Inc. (OTCMKTS:MCUJF) Sees Significant Increase in Short Interest

Medicure Inc.(OTCMKTS: MCUJF)预计空头利息将大幅增加
Financial News Live ·  2022/09/15 21:42

Medicure Inc. (OTCMKTS:MCUJF – Get Rating) saw a significant growth in short interest in August. As of August 31st, there was short interest totalling 200 shares, a growth of 100.0% from the August 15th total of 100 shares. Based on an average trading volume of 14,900 shares, the short-interest ratio is presently 0.0 days.

Medicure Inc.(OTCMKTS: MCUJF — 获取评级)的空头利率在8月份大幅增长。截至8月31日,空头利息总额为200股,较8月15日的100股总额增长了100.0%。根据14,900股的平均交易量,空头利率目前为0.0天。

Medicure Price Performance

Medicure 的价格表现

Shares of OTCMKTS MCUJF remained flat at $0.83 during trading hours on Thursday. The company has a debt-to-equity ratio of 0.03, a current ratio of 1.47 and a quick ratio of 1.16. The firm has a 50 day moving average of $0.80 and a 200-day moving average of $0.84. The company has a market cap of $8.51 million, a P/E ratio of 13.84 and a beta of 0.88. Medicure has a 1-year low of $0.64 and a 1-year high of $1.10.

在周四的交易时段,OTCMKTS MCUJF的股价持平至0.83美元。该公司的债务与权益比率为0.03,流动比率为1.47,速成比率为1.16。该公司的50天移动平均线为0.80美元,200天移动平均线为0.84美元。该公司的市值为851万美元,市盈率为13.84,beta值为0.88。Medicure的1年低点为0.64美元,为1年来的最高水平,为1.10美元。

Get
获取
Medicure
Medicure
alerts:
警报:

About Medicure

关于 Medicure

(Get Rating)

(获取评分)

Medicure Inc, a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market in Canada and the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction.
Medicure Inc是一家生物制药公司,从事加拿大和美国心血管市场人体疗法的研究、开发和商业化。该公司销售和分销 EGRANSTAT 注射剂,这是一种糖蛋白 GP iib/IIIa 受体拮抗剂,用于治疗急性冠脉综合征,包括不稳定型心绞痛和非 Q 波心肌梗死。

See Also

另见

  • Get a free copy of the StockNews.com research report on Medicure (MCUJF)
  • Why Medical Products Maker Repligen May Be A Potential Buy
  • At 10%, Is Arbor Realty Trust Dividend Worth It?
  • Investors Should Tune Into RF Industries
  • 2 Reasons Netflix Might Have Just Bottomed Out
  • Has 3M Reached the Point of Being so Bad It's Good?
  • 免费获取 StockNews.com 关于 Medicure 的研究报告 (MCUJF) 的副本
  • 为什么医疗产品制造商 Repligen 可能成为潜在买家
  • Arbor Realty Trust 的股息为 10% 值得吗?
  • 投资者应关注射频行业
  • Netflix 可能刚刚触底的 2 个原因
  • 3M 已经到了这么糟糕以至于很好的地步了吗?

Receive News & Ratings for Medicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicure and related companies with MarketBeat.com's FREE daily email newsletter.

接收 Medicure Daily 的新闻和收视率 -在下面输入您的电子邮件地址,以通过Marketbeat.com的免费每日电子邮件时事通讯接收Medicure及相关公司最新新闻和分析师评级的简明每日摘要。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发